The MSI-plus assay now also in use for patients across Yorkshire and the Humber, and the south west of England.
With two to three batches of 96 samples per week, a single technician is running the service and achieving less than seven days turnaround time from sample receipt to report.
With competitive pricing and the inclusion of multiple, clinically-actionable biomarkers, the test is saving costs as well as providing timely reports.
This infographic highlights the benefits of using the MSI-plus assay
An independent survey of healthcare stakeholders* in our region found:
- 81% would recommend the test to colleagues (17% were unsure due to a lack of direct experience with the assay)
- 95% indicated that the assay was easily integrated into the existing clinical pathway
* Follow-up qualitative evaluation of the MSI-plus screening assay in a real-world setting; Health Innovation, North East and North Cumbria; 1st July 2024
Cancer Research UK’s Translational Project of the Year
Earlier this year the team won an award from Cancer Research Horizons, the innovation arm of Cancer Research UK, in recognition of their impact in transforming diagnosis for patients.
Alessia Errico, associate director of search and evaluation at Cancer Research Horizons, said of the award: “We named the MSI plus assay as our Translational Project of the Year because it exemplifies the kind of innovation that can truly transform patient care.
“The Newcastle team’s work is a model for how research and clinical practice can come together to improve outcomes for people affected by cancer.”
Patient testimonial
Julien Deckard, 56, of Ingleton near Darlington, has had bowel cancer three times in the last fifteen years and has had multiple surgeries and chemotherapy at the Freeman Hospital. He was tested for Lynch syndrome and found to be positive.
Make a purchaseIt’s five years this month that I had an operation to remove cancer for the second time. It was then that I was tested for Lynch syndrome, and I was advised that my children could be carriers as well.
It was good to know about this and have more information about the increased risk of colorectal cancer. I’m monitored regularly with blood tests every three or four months and I have a CT scan every year.
One of my daughters tested positive and she’s now monitored regularly. Whilst it’s sad I’ve passed this on, it’s reassuring that there’s regular monitoring and early detection for my family if they need it.
October 2025
